You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Optimizing brain penetrance of caspase-6 inhibitors to treat neurodegenerative diseases
SBC: ELGIA THERAPEUTICS, INC. Topic: RPROJECT SUMMARY/ABSTRACT The cysteine protease caspase-6 (Casp6) has been associated with neurodegenerative diseases for over fifteen years. In Alzheimer’s disease (AD), Casp6 is colocalized with amyloid plaques and tau tangles in human brain, and both human and animal model data indicate that activated Casp6 contributes to neuronal inflammation, neurodegeneration, and cleavage of proteins to to ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of Novel Small Molecule Anti-Fibrotic Agent for the Treatment of Systemic Scleroderma
SBC: APIE THERAPEUTICS INC Topic: NHLBIABSTRACT The goal of this STTR proposal is to develop a novel anti-fibrotic agent suitable for oral administration which could be used to safely and effectively treat Systemic Sclerosis (SSc), or Systemic Scleroderma patients. SSc is one of the most disabling and lethal immune-mediated rheumatic disorders. SSc is a rare disease, affecting 40,000-150,000 people in the United States and conferring a ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
VoiceLove: An App-Based COMmunication Tool Designed to Address DeliriUm and Improve Family ENgagement and PatIent/Family SatisfaCtion in CriticAlly Ill PaTiEnts (COMMUNICATE)
SBC: VOICELOVE LLC Topic: N/AICU delirium is a devastating complication of illness, acute trauma, and surgery often resulting in prolonged mechanical ventilation, longer lengths of stay, and long-term disability. Delirium is associated with over 12 times increased odds of developing Alzheimer’s disease (AD) and AD-related dementias (ADRD). In addition, delirium accelerates cognitive decline in AD/ADRD patients. Likewise, pa ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Aerosolized Chemically Modified Tetracycline Nanoformulation for the Treatment of Acute Respiratory Distress Syndrome
SBC: CMTX BIOTECH, INC. Topic: NHLBIPROJECT SUMMARY/ABSTRACT CMTx Biotech is a drug development company working to rescue, develop and commercialize a proprietary clinical-stage drug candidate, incyclinide (CMT-3 / COL-3), for the treatment of sepsis patients at risk of acute respiratory distress syndrome (ARDS). According to the U.S. Centers for Disease Control (CDC), at least 1.7 million American adults develop sepsis annually, re ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Solving Sepsis: Early Identification and Prompt Management Using Machine Learning
SBC: Cohere-Med, Inc. Topic: 300Abstract This fast-track STTR application proposes to enhance, validate, and scale Sepsis Watch, a deep learning sepsis detection and management system built using data from the Emergency Department (ED) Duke University Hospital (DUH). The proposal will extend and enhance Sepsis Watch to EDs, general inpatient wards, and intensive care unit (ICU) settings across multiple health systems in the Unit ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes
SBC: VALA SCIENCES, INC. Topic: NHLBICardiotoxicity is a leading cause of drug discovery attrition across all of preclinical and clinical drug discovery. While the FDA and the Comprehensive in vitro Proarrhythmia Assay initiative (CiPA) are focused primarily on predicting proarrhythmic effects, drug attrition due to cardiomyopathy, or primary cardiac cytotoxicity, may be even more prevalent, is typically currently only carried out vi ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL
SBC: Actinium Pharmaceuticals, Inc. Topic: 102ABSTRACT Despite treatment advances, the prognosis of adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and R/R diffuse large B-cell lymphoma (DLBCL) remains poor. Autologous T- cells modified to express a CD19-targeted chimeric antigen receptor (CAR T-cells) produce durable responses in subgroups of these patients, which has led to FDA approval of two su ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Designing and validating optimal nonaddictive analgesics using the CANDO paradigm
SBC: MEDITATI INC Topic: NIDAABSTRACT We propose a novel holistic paradigm to help solve the opioid crisis by using proteome scale deep learning approaches to design optimal nonaddictive analgesics. We will design compounds that target specific proteins and pathways the combine the pain relieving effects of long acting drugs such as methadone and buprenorphine while modulating additional interactions to ensure optimal pharma ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Controlled-release Microbeads to Replace Growth Factors in Fetal Bovine Serum
SBC: STEM CULTURES LLC Topic: 400Scientific Abstract: The frequent use of fetal bovine serum (FBS) to support cell cultures is challenged by lot-to-lot variability, supply constraints, pathogen contaminants and ethical questions. These issues have increased significance due to the burgeoning use of FBS in cell research and therapy development. FBS has been used for over a century to culture cells, but with the need to define cult ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
A novel producer cell line for more efficient manufacturing of viral vector systems
SBC: CLAIRIgene Topic: 100ABSTRACT Significant advances in the specific targeting of delivery vectors and the increased therapeutic efficacy of such vectors for gene delivery have been made, stimulating major interest in the development and commercialization of therapeutic products focused on gene therapy indications. CLAIRIgene LLC focused on the development and optimization of various viral gene-to-cell transfer delivery ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health